肥満合併2型糖尿病患者へのSGLT2阻害薬の追加治療に関する短期効果

抄録

Aim: To investigate the 6-month efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in obese patients with type 2 diabetes (T2DM) in Japan.

Methods: We retrospectively collected data from patients with T2DM with a body mass index (BMI) ≥25 kg/m² undergoing antidiabetic treatment at the Diabetes Center, Tokyo Women's Medical University Hospital, from April to October 2015. We selected 34 patients with SGLT2i added-on (S group), and 31 age-, BMI-, sex-, duration of diabetes-, HbA1c-propencity score matched patients who continued their treatment without SGLT2i (C group).

Result: After 6 months, the body weight (BW), BMI, and HbA1c decreased, and the hematocrit increased significantly in the S group compared to the C group. Sixty percent of patients in the S group showed a decrease in HbA1c and 90 % of them showed a decrease in BW. In the S group, patients who showed decreased HbA1c (n=23) had significantly higher baseline HbA1c, alanine transaminase (ALT), and aspartate transaminase (AST) levels than those without a decrease in HbA1c (n=11).

Conclusion: The 6-month evaluation revealed the potential of SGLT2i add-on therapy as a new treatment option for obese patients with T2DM, especially in those with visceral obesity with worse glycemic control.